TORONTO, ON--(Marketwired - Mar 2, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) Provides update on the AMFIL GroZone technology and its related investment in AMFIL Technologies Inc. for the medical marijuana industry; Moves towards implementation in Medicated Markets, California Medical Marijuana Operations. Highlights projected goals towards the venture for the month of March.

AMFIL Technologies Inc. has informed Easton Pharmaceuticals that while it has taken longer than originally anticipated to get their audited financial statements filed, they have received confirmation from their auditors that the process will be completed and statements filed before the end of this month. It has been indicated that AMFIL will not delay in providing consistent updates on the developments and achievements for the GroZone product line that have taken place behind the scenes over the past few months. These include all orders and pending order backlog for GroZone system adoption by the Medical Marijuana industry as a pesticide and bacteria free crop insurance policy and standard for growing.

The President of the GroZone project and inventor of the technology, Mr.Ambrose Fillis is scheduled to be interviewed by the Cannabis Financial Network. More detailed information on the technology, products and goals will be explained in more detail in the interview to be subsequently aired at a future day and time.

Mr. Ambrose Fillis will also be making another trip to Colorado later this month as Today's Health Care is in its second harvest cycle after having the GroZone 60 system integrated. Additional staff will be trained on the machine to ensure it's use is being maximized and the grow process is taken full advantage including all aspects the system has to offer. Feedback and comparable testing on potency and yields from the first cycle to the second as well as compared to the other rooms in the facility not utilizing this system will be available upon the completion of the second harvest cycle and will be jointly posted by AMFIL and Easton.

AMFIL has again extended its gratitude to Easton for the initial investment into the first GroZone unit manufactured for the Colorado grow facility and both parties looks toward upgrading and expanding the relationship which includes additional funding. Funding will assist in the manufacturing of additional GroZone machinery including the smaller scale retail units which Easton will have the ability to market through its retail website at The cost is anticipated to be priced very affordably to attract all personal production licensees at between $2499 and $2999 a unit. Commercial units range from approx. $50k to $1M depending on the customization, facility specifications and needs. These units can be used for any indoor or outdoor contained growing environments. The retail GroZone system will be launched and have pictures, specifications, marketing materials and will be ready to start receiving purchase orders later this month once the patent has been submitted for filing. The documents have been completed and are currently being reviewed by a patent attorney for filing this month

AMFIL, Easton and Medicated Markets will be discussing an aqueous based GroZone unit to be manufactured by AMFIL at cost for Medicated Markets California operations. Discussions will take place next week, which will include among other items an overview of the specifications that will be required to custom tailor the manufacturing to meet and exceed the needs of the Medicated Markets operation. The unit will feed the irrigation system by providing ozonated, biologically stable water with high levels of oxygen to increase and stimulate growth and eliminate any possibilities of bad bacteria while simultaneously controlling and purifying the water source to ensure no unforeseen fluctuations in mineral contents, associated with the grow process. This will allow constant feedback in real-time, highlighting the exact concentration levels of various trace elements, minerals and other substances the plants are receiving at any given time. This will eliminate any potential of a wasted or lost portion of crop which has been seen in numerous grow facilities to date by the growers not being able to monitor and realizing only at the end of the grow cycle that plants were exposed and succumb to elevated and unacceptable bacteria levels, mold or algae development or unknown and improperly purified water supply.

Once a deal is reached on the optimal unit for the Medicated Markets facility, AMFIL will provide Easton with ongoing updates on the manufacturing process including pictures, videos of its progress and will be forwarded to Mr. Ambrose Fillis and to California to fully integrate the machine into the facility and teach the staff how to get the maximum potential out of the machines. The assembly will take approx. two to three weeks to complete and training will be another week. We would like to have this process completed by the end of March to early April.

Since ozone is a derivative of oxygen being 03, by providing increased oxygen levels, in effect feeding the plants with a green, healthy all natural steroid, (while killing and controlling pesticides, bacteria, etc..) the plants will respond favorably producing a healthier, more robust life cycle thus increasing quality and quantity of product. Crystallization, potency and overall yield of the plant should be noticeably increased which will lead to either more volume or higher sale prices of the cannabis as well as higher return off of the by-products and extract materials. The installation of the system will also allow the next Medicated Markets grow cycle to be completed, chemical and pesticide free which will lead to an organic product which grants higher sale prices.

The installation of the system should command a revised guidance and revenue projection from Medicated Markets on next years crop and will verify from yet another grow facility the importance of the GroZone product line to the medical marijuana industry overall. Being conservative, it is expected that after installation of the system, the harvest should see a 10% - 30% increase in overall yield along with the potency levels or percentage of THC at elevated rates. This does not include the sale of all the extract material created from the trimming process. High quality trimmings are sought out by a number of edible and extract based companies and premiums are paid for quality material with high potency. Feedback on the fully integrated GroZone systems leads Medicated Markets to believe that crystallization and overall extract material will also create a revenue increase on the by-products created during the grow process.

Both AMFIL Technologies Inc. and Easton Pharmaceuticals Inc. are pleased and excited about the progress to date as well as what the future holds for the GroZone product line within the Medical Marijuana Industry and are looking forward to continue the business relationship created at the onset of product development. Shareholders will be kept informed of the progress with the AMFIL, Easton and Medicated Markets relationship as they develop.

About Easton Pharmaceuticals
Easton Pharmaceuticals is a specialty pharmaceutical company involved in various pharmaceutical sectors and others industries such as medical marijuana. The Company previously developed and owned an FDA approved wound healing drug and currently owns topically-delivered drugs and other therapeutic products that are all in various stages of development. Easton has completed an acquisition that grants 40% ownership interest in Medicated Markets International LLC assets; a California Licensed Medical Marijuana Grower on 20 acres (3 acre growing area). Easton has also made additional investments into AMFIL Technologies and their GroZone anti-microbial airflow system needed for growing pesticide free medicine, and currently have an exclusive option to purchase up to 49% in a medical marijuana grow-op business post granting of license from Health Canada in Port Perry, Ontario, which has received a letter to build from Health Canada. The company's gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.

For More Information Visit:

Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope," "positive," "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals would be classified as speculative and may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.

Contact Information:

Carla Pepe
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192